Transgene to Present Phase I Data on Cancer Vaccine TG4050 at ASCO 2025

Transgene will unveil 24-month disease-free survival data from its Phase I trial of TG4050 during the ASCO Annual Meeting from May 30 to June 3, 2025. TG4050, an individualized cancer vaccine, is developed using Transgene’s myvac® platform in collaboration with NEC's AI technology. The data will be presented on June 1st at 1:30 p.m. CDT in Chicago.

The trial targets HPV-negative head and neck cancers. Key outcomes being shared include safety, disease-free survival after two years, and updated immunogenicity data. Following positive results from Phase I, the study has progressed to a Phase II trial, currently enrolling patients internationally.

Prof. Le Tourneau from Institut Curie expressed the significance of presenting these findings at ASCO. Dr. Emmanuelle Dochy, Transgene's CMO, emphasized the importance of TG4050 for advancing cancer treatment. A poster on TG4001 will also be presented, focusing on cervical cancer treatment options.